|
advertisement
|
Company Overview: |
| Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. |
Products and Services: |
Oxford BioMedica's products use genes as the mediators of a therapeutic effect and/or immune response. The Company’s gene therapy products deliver therapeutic molecules in vivo whilst its gene-based immunotherapy products deliver genes that recruit the patient’s immune system to mediate a therapeutic effect. The genes are delivered by the Company’s highly engineered viral systems.
Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes TroVax®, a cancer immunotherapy, which was recently licensed to Sanofi-Aventis for global development and commercialisation. TroVax is in Phase III development for renal cancer (see www.trovax.co.uk) and Sanofi-Aventis is implementing a development plan for metastatic colorectal cancer. The recent acquisition of Oxxon Therapeutics adds a Phase II cancer immunotherapy for melanoma, HI-8® MEL, to the Company's pipeline. Other oncology product candidates include a gene therapy, MetXia®, which is in Phase II development for pancreatic cancer, and a preclinical targeted antibody therapy, which is being developed in collaboration with Wyeth. In neurotherapy, the Company's lead product, ProSavin, is expected to enter clinical trials in Parkinso's disease in 2007. The preclinical pipeline includes gene-based products for vision loss, motor neuron disease and nerve repair. The acquisition of Oxxon also provides a platform for the development of therapeutic vaccines for infectious diseases. |
|
|
|
|
Back to Top
|
|
Working @ Oxford BioMedica
Have your shout about working or interveiwing at Oxford BioMedica
1 message posted
Message Posted:
Working @ Oxford BioMedica
Share your experiences about working, interviewing or applying for a job at Oxford ...
Author: Obi Posted: 4/5/2007 5:05:20 AM |
View or add comments about Oxford BioMedica
Back to Top
|
Oxford BioMedica in the News
- OXFORD BIOMEDICA'S TROVAX RECEIVES POSITIVE RECOMMENDATION FOR ORPHAN DRUG DESIGNATION IN RENAL CANCER FROM EMEA
Published: Friday, December 08, 2006
- Oxford Biomedica TroVax breakthrough
Published: Friday, December 08, 2006
- Oxford Biomedica Announces Board Appointment
Published: Saturday, February 04, 2006
- Oxford Biomedica Receives Notice Of Allowance For Us Lentivector Patent
Published: Saturday, April 02, 2005
- Oxford Biomedica Receives Notice of Allowance For US Lentivector Patent
Published: Tuesday, March 29, 2005
View more news about Oxford BioMedica
Back To Top |
|
|
|
|
Categories:
|
Biotechnology
|
|
Back to Top
|
|
|
|